Key facts
- This page summarizes Christopher A. Toth's Form 4 filing for BAXTER INTERNATIONAL INC (BAX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 04 Feb 2025, 16:03.
Christopher A. Toth - 31 Jan 2025 Form 4 Insider Report for BAXTER INTERNATIONAL INC (BAX)
- Reporting relationship
- EVP, Group Pres, Kidney Care
- Issuer ticker
- BAX
- Reported as of
- 31 Jan 2025
- Net transaction value
- -$826,112
- SEC form
- 4
- Accepted by SEC
- 04 Feb 2025, 16:03:52 UTC
- Prior SEC filing
- 03 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kimberly Olson, as attorney in fact for Christopher A. Toth
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher A. Toth filed Form 4 for BAXTER INTERNATIONAL INC (BAX) on 04 Feb 2025.
Change
- Previous filing in this sequence was filed on 03 Jan 2025.
- Current net transaction value: -$826,112.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BAX
transaction
Common Stock, $1 par value
Tax liability
- Transaction value
- $826,112
- Shares
- -25,372
- Change %
- -19%
- Price
- $32.56
- Shares after
- 105,186
- Date
- 31 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Christopher A. Toth is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the delivery of shares on January 31, 2025 from the settlement of restricted stock units granted on March 6, 2024. These shares vested on January 31, 2025 in accordance with the terms of that Equity Purchase Agreement, dated as of August 12, 2024 (as amended), by and among Baxter International Inc. and certain Carlyle affiliates (the "EPA").
Footnote F2
Adjusted to reflect (i) automatic reinvestment of dividends, and (ii) the number of shares forfeited by the reporting person in connection with the closing of the EPA, as further described in the Issuer's Form 8-K filed on February 3, 2025.